Clinical Trial

Comparison of Efficacy in SBRT of Large HCC With or Without TACE

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 27, 2023 (before its estimated August 1, 2023 completion). Its status may not reflect the trial's current state.
Summary
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-08-11; most recent amendment 2023-06-24.
Trial Details
NCT Number NCT04512846
Lead Sponsor Beijing 302 Hospital
Conditions Large HCC Patients, Stereotactic Body Radiation Therapy, Transcatheter Arterial Chemoembolization
Enrollment 100 participants
Start Date 2020-08-01
Primary Completion 2023-08-01 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2023-06-27